Drug Type Biological products |
Synonyms a reduced biocompatible ceramic biomaterial that can be suspended and injected into myofascial compartments to degrade and release ions over time, promoting growth factor secretion and the formation of a robust vascular network |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Muscular Dystrophy, Duchenne | Preclinical | United States | 17 Sep 2024 |